NKTR — NEKTAR THERAPEUTICS

—
Nasdaq · Health Care · Pharmaceuticals · CIK 906709 ·
Last close
$35.91
Market Cap
$1.23B
52W High
$109.00
52W Low
$33.40
ADV30
812,995
Next earnings
2026-11-12
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 9,386,000 — -59,306,000 -55,651,000 1,037,251,000 34,686,000 187,529,000
Jun 2026 10,131,000 — -41,763,000 -40,622,000 1,095,129,000 39,267,000 192,008,000
Mar 2026 10,861,000 — -38,258,000 -44,904,000 763,271,000 149,578,000 187,055,000
Dec 2025 21,807,000 21,807,000 -19,090,000 -36,079,000 280,406,000 15,116,000 190,574,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-233,788,000
Investing CF
$-844,400,000
Financing CF
$1,074,466,000
CapEx
$-244,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-6.70
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-3,845,812,000
Inventory
—
Receivables
$4,756,000
ST Investments
$645,074,000
EBIT TTM
$-122,150,000
Pretax Income TTM
$-153,114,000
Interest Exp TTM
$30,964,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$52,185,000
EBITDA
$-157,759,008
Free Cash Flow
$-134,766,368
Enterprise Value
$788,133,248
Total Cash
$614,356,992
Total Debt
$128,668,000
Shares Out
34,142,994
Trailing EPS
$-18.92
Book Value
$24.86
ROE
-37.9%
ROA
-14.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 55,232,000 -130,771,000 -164,076,000 280,406,000 190,574,000 89,832,000 -208,511,000
Dec 2024 98,427,000 -129,918,000 -118,961,000 303,850,000 243,113,000 60,737,000 -175,709,000
Dec 2023 90,122,000 -135,225,000 -276,056,000 398,033,000 267,046,000 130,987,000 -192,606,000
Dec 2022 92,055,000 -240,236,000 -368,198,000 710,600,000 343,962,000 366,638,000 -304,007,000

TTM Snapshot

Revenues TTM
$54,589,000
NetIncome TTM
$-157,127,000
OpCashFlow TTM
—
Assets (Latest)
$1,095,129,000
Forward EPS
$-10.31

Max Pain — expiry 2027-01-15

max pain strike: $45.00 · spot: $34.42 · call oi: 3,335 · put oi: 3,194

Peers — same industry

TickerNameMarket CapLastDaily %
AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL $1.23B $13.14 —
SLN Silence Therapeutics plc $1.23B $19.80 —
SLNCF Silence Therapeutics plc $1.22B $6.53 —
KARD Kardigan, Inc. $1.23B $13.19 —
AMPH Amphastar Pharmaceuticals, Inc. $1.24B $29.10 —

News headlines (Yahoo Finance, 1h cache)

Nektar (NKTR) Q3 2026 Earnings Call Transcript
2026-11-13 15:29 · Yahoo
Nektar Therapeutics Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call
2026-11-13 04:14 · Yahoo
Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates
2026-11-12 22:05 · Yahoo
Nektar: Q3 Earnings Snapshot
2026-11-12 21:28 · Yahoo
Nektar Therapeutics Announces Third Quarter 2026 Financial Results
2026-11-12 21:15 · Yahoo
Nektar Therapeutics to Participate in Two Investor Conferences in November
2026-11-11 21:15 · Yahoo
How New Eczema Drug Trials Will Impact Nektar Therapeutics (NKTR) Investors
2026-11-07 22:12 · Yahoo
Is Nektar Therapeutics (NKTR) Overvalued After A 407% Three Year Run?
2026-11-06 07:09 · Yahoo
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
2026-10-29 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.